Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer

Anti-Cancer Drugs

Volumn 8, Issue SUPPL. 2, 1997, Pages

  Zalcberg, John ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Efficacy; Raltitrexed; Safety; Tolerability; Tomudex

Indexed keywords

FLUOROURACIL; RALTITREXED;

ALOPECIA; ASTHENIA; BLEEDING; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 0030823834     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199708002-00004     Document Type: Conference Paper

References (17)

1. Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 1990, 26:1167-1256.
2. Boring C, Squires TS, Tong T: Cancer statistics. CA Cancer J Clin 1993, 43:7-26.
3. August DA, Ottow RT, Sugarbaker PH: Clinical perspective of human colorectal cancer metastases. Cancer Metastases Rev 1984, 3:303-324.
4. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994, 330:1136-1141.
5. Petrelli N, Herrera L, Rustum Y, et al.: A prospective randomized clinical trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5:1559-1565.
6. Petrelli N, Douglas HO, Herrera L, et al.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989, 7:1419-1426.
7. The Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896-903.
8. Jackman AL, Taylor GA, Gibson W, et al.: ICI D 1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991, 5:5579-5586.
9. Jackman AL, Farrugia DC, Gibson W, et al.: ZD1694 ('Tomudex'): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A:1277-1282.
10. Clarke SJ, Ward J, de Boer M, et al.: Phase I study of the new thymidylate synthase inhibitor 'Tomudex' (ZD1694) in patients with advanced malignancy [abstract]. Ann Oncol 1994, 5 (suppl 5):132.
11. Cunningham D, Zalcberg JR, Rath U, et al. and the 'Tomudex' Colorectal Cancer Study Group: 'Tomudex' (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995, 31A:1945-1954.
12. Zalcberg J, Cunningham D, Green M, et al.: ZD 1694: a novel thymidylate synthase Inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996, 14:716-721.
13. Cunningham D, Zalcberg JR, Rath LI, et al.: Final results of a randomized trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996, 7:961-965.
14. Kerr DJ: Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997, 8 (suppl 2):S11-S15.
15. Judson IK: 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies. Anticancer Drugs 1997, 8 (suppl 2):S5-S9.
16. Adenis A, Bonneterre J, Pion JM, et al.: Unexpected fatal toxicity related to low dose leucovorin with 5-fluorouracil: treatment in metastatic CRC. Ann Oncol 1993, 4:174-175.
17. Elliott R: An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer. J Oncol Pharm Pract 1996, 2:186-190.